Glycaemic control remains central in type 2 diabetes mellitus management: key learnings from the latest International Diabetes Federation guidelines - PubMed
11 hours ago
- #IDF Guidelines
- #Glycaemic Control
- #Type 2 Diabetes
- Glycaemic control is central in managing type 2 diabetes mellitus (T2D).
- The 2025 IDF guidelines highlight global healthcare disparities, with 80% of T2D patients in low-to-middle-income countries (LMICs).
- SGLT2 inhibitors and GLP-1 receptor agonists show cardiovascular-kidney protection in high-risk T2D patients.
- IDF proposes two standards-of-care: 'optimal' and 'basic'.
- Early glycaemic control with conventional glucose-lowering drugs (GLDs) prevents complications and preserves quality of life.
- Multifactorial management using effective GLDs and organ-protective drugs improves outcomes.
- Individualised treatment regimens with shared decision-making maximise benefits and minimise harm.
- Metformin remains a foundation therapy; no evidence supports first-line SGLT2i or GLP-1 RA monotherapy in low-risk individuals.
- Sulphonylureas are effective and affordable, important in low-resource settings.
- Initial combination therapy achieves early glycaemic control better than stepwise GLD addition.